Director Steven Paul, M.D. to retire from Alnylam Board effective April 16, 2022

ALNYLAM PHARMACEUTICALS, INC.

Steven Paul resigns from Board effective April 16, 2022; no disagreement with company operations.
Board size reduced from 11 to 10 members upon Dr. Paul's departure.
Colleen F. Reitan joins PC&C Committee; Amy W. Schulman remains Chair.
Dr. Paul served on Alnylam Board since September 2010; praised for decade of service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Steven M. Paul

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2022-04-16
Filed: April 5, 2022, 7:59 PM ET

On March 31, 2022, Steven M. Paul, M.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board effective as of April 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven M. Paul resigned as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On March 31, 2022, Steven M. Paul, M.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board effective as of April 16, 2022.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-096176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.